Long-Term Safety of Baricitinib in Pediatric Patients With Atopic Dermatitis Aged 2 to <18 Years With Up to 5.2 Years of Exposure
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease that frequently begins in childhood and can significantly impact quality of life. Baricitinib, an oral selective Janus kinase inhibitor, has demonstrated efficacy and an acceptable safety profile in pediatric patients with moderate-to-severe AD...